ArticleInflammopharmacology2026
Quercetin-loaded exosomes derived from human umbilical cord mesenchymal stem cells alleviate microglia-mediated neuroinflammation via an anti-inflammatory mechanism.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroinflammation is central to the progression of neurodegenerative diseases (NDs), with microglia contributing through the release of pro-inflammatory and oxidative mediators. Although quercetin (Que) possesses potent anti-inflammatory and antioxidant properties, its clinical application is limited by poor solubility and bioavailability. Umbilical cord mesenchymal stem cells (UC-MSCs)-derived exosomes (Exo) offer a promising delivery system to enhance Que efficacy. This study investigated the anti-inflammatory effects of Que-loaded Exo (Que-Exo) using an in vitro neuroinflammation model. Exo were isolated from UC-MSC-conditioned media via ultracentrifugation and loaded with Que through sonication. Characterization of Exo and Que-Exo was performed using dynamic light scattering, zeta potential analysis, transmission electron microscopy, and western blotting. In vitro release and cellular uptake studies assessed Que-Exo release profiles and their internalization by HMC3 microglial cells. Neuroinflammation was induced in HMC3 cells using lipopolysaccharide (LPS). The effects of Que-Exo on pro-inflammatory cytokine and enzyme expression, nitric oxide (NO) production, and inflammatory signaling pathways were evaluated using flow cytometry, the Griess assay, and western blotting. In vitro release from Que-Exo demonstrated improved stability and controlled delivery, while fluorescence imaging confirmed efficient uptake of Que-Exo by HMC3 cells. Mechanistically, Que-Exo inhibited NF-κB nuclear translocation, a key regulator of pro-inflammatory mediator transcription. Que-Exo pretreatment significantly reduced TNF-α, IL-6, iNOS, and COX-2 expression and suppressed NO synthesis in LPS-stimulated cells. Overall, Que-Exo exhibited superior anti-inflammatory activity compared to Exo and free Que, highlighting the synergistic effect of exosomal delivery in enhancing Que bioavailability and therapeutic efficacy against neuroinflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.